Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.
Year: 2026
Type: article
Study design: Observational Study
Abstract: OBJECTIVES: We aimed to estimate whether adding oral glucocorticoids to ILD-modifying therapy improves 12-month lung outcomes in systemic sclerosis-associated interstitial lung disease (SSc-ILD). METHODS: We emulated a target trial using the EUSTAR database. Eligible adults with confirmed SSc-ILD initiated an eligible ILD-modifying therapy at baseline (T0), either alone or with oral glucocorticoids added (prednisone-equivalent dose ≤20 mg/day). Follow-up ended at the visit closest to 12 months within a 9 to 15-month window. The primary outcome was the between-group difference in change in FVC (% predicted). Secondary outcomes were progressive lung fibrosis and isolated DLCO decline ≥15%. We used multiple imputation (m=80), stabilised inverse probability of treatment weighting, robust variance estimators and Rubin's rules. RESULTS: Of 443 patients, 185 (41.8%) received oral glucocorticoids with ILD-modifying therapy and 258 (58.2%) received ILD-modifying therapy alone. Adding oral glucocorticoids was not associated with improved 12-month FVC. The adjusted mean difference in FVC change was -2.10 percentage points (95% CI -4.68 to 0.47; p=0.11). There was no clear difference in progressive lung fibrosis (RR 1.40, 95% CI 0.83 to 2.35) or isolated DLCO decline ≥15% (RR 0.81, 95% CI 0.39 to 1.69). Findings were consistent in the truncated-weight sensitivity analysis. CONCLUSION: Adding oral glucocorticoids to ILD-modifying therapy was not associated with improved 12-month FVC in SSc-ILD. Secondary outcomes were sparse and should be interpreted cautiously.
Source: Arthritis Care & Research
DOI: 10.1002/acr.80205
Institutions: Centre National de la Recherche Scientifique, Université de Montpellier, Physiologie et Médecine Expérimentale du Coeur et des Muscles, Sapienza University of Rome, University of Zurich, University Hospital Zurich, University of Pecs, Marche Polytechnic University, Inserm, Université de Lille, Centre Hospitalier Universitaire de Lille, Institute for Translational Research in Inflammation, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Centro Académico de Medicina de Lisboa, Unidade Local de Saúde Santa Maria, University of Milan, Carol Davila University of Medicine and Pharmacy, Kocaeli Üniversitesi, Medical University Plovdiv, University of Debrecen, University of Geneva, University Hospital of Geneva
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,640
OpenAlex ID: W7225848216
